Overactive bladder (OAB) is a chronic condition affecting both men and women, with prevalence increasing with age. Antimuscarinics form the cornerstone of treatment of OAB. Fesoterodine, a nonselective muscarinic-receptor antagonist, was approved by the US Food and Drug Administration in late 2008 for once daily, oral administration in the treatment of OAB to relieve the symproms of urinary urge incontinence, urgency, and frequency.
INTRODUCTION
Overactive bladder (OAB) has been defined by the Standardisation Sub-Committee of the International Continence Society as urgency, with or without urge incontinence, usually with frequency and nocturia.' OAB is a highly prevalent symptom complex. In a population-based survey of 16,776 men and women aged :2:40 years conducted by Milsom et a1 2 in 6 countries, by telephone Ot direct interview, the prevalence of OAB in Europe was estimated to be 15.6% in men and 17.4% in women, with an overall prevalence of 16.6%. In a survey of 11,740 Americans, overall prevalence of OAB was 16.0% in men and 16.9% in wornen.f The symptoms and reduced quality of life (QoL) associated with OAB cause distress in many patients.r OAB is a chronic condition occurring in both men and women, with a prevalence that increases with advancing age. The pathophysiology of OAB is complex. It is primarily caused by detrusor overaetivity, defined as involuntary contractions of the detrusor muscle during the bladder filling phase as a result of continuous and increasing afferent activity from the bladder. 4 During normal function, the bladder should be relaxed as urine fills it. The cause of OAB is unknown; however, 3 main theories of detrusor overacriviry have been proposed. The myogenic theory suggests that partial denervarion of the detrusor results in alterations in the properties of the detrusor muscle cells leading to increased excitability and, therefore, producing increases in involuntary pressure.? The neurogenic theory suggests that damage to central inhibitory pathways can unmask primitive voiding reflexes that trigger detrusor overactivity.? A third theory, the autonomic bladder hypothesis, was proposed in 2004.7 It suggests that detrusor overactivity is a consequence of inappropriate activation or modulation of phasic activity.
OAB is not purely a bladder condition, but may also involve pelvic floor-muscle dysfunction and behavioral issues." No drug can ever correct all facets of this multifactorial disorder. In almost all OAB groups, no curative treatment can be offered. The principles of treatment are to increase voided volume, decrease urgency, and reduce urinary urge incontinence (UUn episodes.f Current treatments include lifestyle interventions, bladder training and pelvic floor exercises, pharmacotherapy, and surgery."
Acetylcholine released from cholinergic nerves stimulates muscarinic receptors and mediates the main part of the voiding contraction in humans.!" There are 5 different subtypes of muscarinic receptors (MI-M5). They are all widely distributed throughout the body. In the human bladder, the M2 and M3 receptors can be found, with the ratio being 3:1, respectively. Despite the predominance ofM2 receptors, several investigators have found that the pharmacologically defined M3 receptors mediate bladder contraction. The complexity of the muscarinic regulation of bladder function makes the relative importance of the different muscarinic-receptor subrypes difficult to assess.
Antimuscarinic medications, aimed at blocking cholinergic-receptor activity in the bladder, are the primary pharmacotherapeutic options for OAB. Currently, a variety of antimuscarinics are used for the management of OAB: oxybutynin, tolterodine, propiverine, solifenacin, darifenacin, and trospium chloride. 4 However, antimuscarinics are associated with adverse effects (AEs) (eg, constipation, dry mouth, blurred vision, drowsiness) that impact both compliance and persistence with long-term treatment. None of the currently available medications are ideal in terms of efficacy and tolerability. 11 Fesorerodine is a novel, competitive, muscarin ic-receptor ant agonist that has recently been approved for the tr eatment of OAB as a pro longed-release tabl et. 12 The aim of th is review was to provi de an overview of the clinical tri al data for fesorerod ine and its present status in the man agem ent of OAB .
METHODS
A search of the literature was performed using the MED LINE and Goog le Scholar databases with th e term s fesoterodine, ooeractiue bladder, and muscarinic antagonists. Th e literat ure research was limited to Eng lish-language clinical tr ials, meta-analyses, randomized cont rolled tr ials (RCTs), reviews, and conference abst racts pub lished from June 1, 1999 to Decem ber 1, 2009 . Articles were required to p resent th e mechanism of action, pharmacok inetics, and data from clini cal trials. T he parameters measured were to lerability, efficacy, and health-related QoL (H RQoL). Trials involving animals and Ph ase I studies were excluded .
RESULTS

SEARCH RESULTS
The initial lit erat ure search yielded 4 8 papers. A tot al of 20 art icles fulfilling th e inclusion crite ria were selected . T hese included 4 each of Ph ase II , III , and III b RCTs, 3 post hoc analyses, and 3 clinica l tr ials. In addition to th e full art icles, th e relevant references of th e selected articles were obtained.
MECHANISM OF ACTION
Fesot erodine is a compet itive, specific, and nonselective m uscarinic-recepto r antagonist . By prevent ing the bin ding of acetylcholine to th ese receptors, it red uces smoo th -mu scle tone in the bladder, allowing th e bladder to retain large r volumes of urine and redu cing th e nu m ber of inconti nence episodes. 13
CHEMISTRY
Fesoterodine is isobutyric acid 2-« R)-3-diisopropylammo nium-l -phenylpropy l)-4-(hyd roxymethyl) pheny l ester hyd rogen fumara te. T he empirical formula is C30H 41NOr Th e structura l form ula is shown in the figure .14 .
PHARMACOKINETICS
Aft er ora l adm in ist rat ion , fesot erodine is well absorbed . It acts as a p rodrug. It undergoes rapid and exte nsive hydrolysis by no nspecific plasma est erases to for m its active m etabo lite , 5-hyd rox ymethyl rolr ercd in e (5 -HMT), whic h is responsib le for its antimuscari nic ac t iv ity.l ? S-H MT is also t he act ive me taboli te of rolr erodine, but th e metabol ism is m ed iated by cytoc hrom e P4 S0 (CY P) 2D6 in liver. D ue to rap id conversion, fesote rodine cannot be detected in bl ood . Bioavailabili ty of th e act ive met abolite is 52 % . After si ngle or mu lti ple oral dai ly doses from 4 to 28 mg, S-H MT exhi b it s lin ear, dose-propor t ional p harmacokinetics. The T ma x of S-HMT is -5 hours. No accu mul at ion occurs afte r multiple-dose admin istration. Food does not appear to have a clinically relevant effect on the pharmacokinetics of fesorerodine.J'' 5-HMT has low plasma protein binding (-50%). The mean steadystate volume of distribution after intravenous infusion of 5-HMT is 169 L l4 5-HMT is further metabolized in the liver via 2 major pathways involving CYP2D6 and CYP3A4. None of the metabolites contribute significantly to the amimuscarinic activity of fesorerodine.I'' Metabolism via CYP2D6 varies in different individuals. The majority of the population are referred to as extensive merabolizers while a subset of individuals (-7 % of whites and -2% blacks) are considered poor rnetabolizers. The C m ax and AVC of 5-HMT are increased 1.7 and 2.0 times, respectively, in poor metabolizers of CYP2D6 compared with extensive merabolizers.l? However, mean T m ax and t 1l2 of5-HMT do not differ with regard to CYF2D6 rnerabolizer status. Similarly, the extent of systemic accumulation at steady state is similar in extensive and poor metabolizers. The elimination of 5-HMT depends on hepatic metabolism and renal excretion. After oral administration of fesoterodine, -70% of the administered dose is excreted in urine as metabolites and a smaller amount (-7%) is recovered in the feces. The t 1 / 2 of 5-HMT following oral administration is -7 hours and is -4 hours following intravenous infusion.!"
No apparent difference has been observed in the pharmacokinetics of fesoterodine between healthy white or black subjecrs.l" The pharmacokinetics of fesorerodine are not significantly influenced by age and gender and no dose adjustment is required. 12 The pharmacokinetics of fesoterodine have not been evaluated in pediatric patients.
In patients with mild or moderate renal insufficiency (creatinine clearance [CrCl} of 30-80 mLlmin), C m ax of 5-HMT is increased up to 1.5 times compared with healthy subjects. In patients with severe insufficiency (CrCi <30 mUmin), C max is increased 2 times compared with healthy volunteers. 17 No dose adjustment is recommended in patients with mild or moderate renal insufficiency. Therefore, a dose of fesoterodine, up to 8 mg once daily, may be administered. However, in patients with severe renal insufficiency, the recommended dose of 4 mg once daily should not be exceeded. In patients with moderate (Child-Pugh B) hepatic impairment, C m ax and AUC of the 5-HMT are increased 1.4-and 2.1-fold, respectively, compared with healthy subjects. No dose adjustment is recommended in patients with mild or moderate hepatic impairment. Fesoterodine has not been srudied and is, therefore, not recommended in patients with severe hepatic impairment (Child-Pugh C). IS
DRUG INTERACTIONS
To assess drug-drug interactions of fesorerodine, a CYP3A4 inhibitor (ketoconazole), inducer (rifampicin), and substrates (erhinyl esrradiol and levonorgestrel) were administered. 19 Concomitant administration of keroconazole 200 mg twice daily with fesoterodine 8 mg once daily resulted in a 2.0-and 2.3-fold increase in the C max and AUC of 5-HMT in CYP2D6 extensive and poor metabolizers, respectively. Therefore, the maximum dose of fesoterodine should be restricted ro 4 mg when used concomitantly with potent CYP3A4 inhibitors such as keroconazole, itraconazole, and clarithromycin. The effects of weak or moderate CYP3A4 inhibitors have not been evaluated in any study.l" Following concomitant administration of rifampicin 600 mg once a day, C m ax and AUC of 5-HMT decreased by -70% and -75%, respectively, after oral administration of fesoterodine 8 mg.t s Concomitant adminisrration of CYP3A4 inducers may lead to subtherapeutic plasma levels. In the presence of fesoterodine, there are no changes in the plasma concentrations of combined oral contraceptives containing ethinyl estradiol and levonorgesrrel.
Concomitant adminisrration of fesoterodine with other antimuscarinics and other drugs with anticholinergic properties (eg, amantadine, tricyclic antidepressants) may aggravate AEs such as constipation, dry mouth, drowsiness, and urinary retention. Therefore, caution must be exercised while administering antimuscarinics to patients already receiving fesoterodine.l''
FESOTERODINE CLINICAL TRIAL DATA
Clinical Efficacy
In a Phase II, multicenter, double-blind, randomized, placebo-controlled trial by Nitti et al,2o the efficacy, tolerability, and dose-response relationship of sustained-release fesoterodine were studied in patients with GAB (Table I) . After a I-week placebo run-in, 173 patients with ::>8 micturitions/24 hours and ::>2 UUI episodes/week during the run-in period were randomized to receive fesoterodine 4, 8, or 12 mg, or placebo once daily for 8 weeks (44, 47,39, and 43 patients, respectively). The primary efficacy end point was the number of micturitions per 24 hours. The secondary efficacy end points were UUI episodes per week and mean volume voided (MVV) per micturition. Dose-response relationship was described by fitting a linear regression function test for a nonzero slope with power of::>80%. Multiple regression analysis showed statistically significant linear dose-response improvement from baseline and placebo in the primary efficacy variable. Statistically significant improvement was observed with fesorerodine 4, 8, and 12 mg compared with placebo (P < 0.04, P = 0.001, and P < 0.007, respectively). The change from baseline to end of treatment in the MVV per micturition was 27.94, 58.96, and 92.34 mL in the fesoterodine 4-,8-, and l2-mg groups and 4.53 mL in Table I :u the placebo group. Statistically significant changes in the secondary variables were observed 2 weeks after randomization. In a Phase III, double-blind, randomized, placebo-controlled, multicenter erial by Nitti et al,21 the efficacy and tolerability of fesoterodine 4 and 8 mg were studied in patients with GAB (Table II) . Patients included men or women aged ::::18 years with GAB symptoms for ::::6 months with urinary urgency (::::8 micturitions per 24 hours) and UUI (::::6 episodes during the 3-day diary period) or ::::3 episodes of UUI during the 3-day diary period. After a 2-week placebo run-in period, the eligible patients were equally randomized to I of 3 groups: fesoterodine 4 mg once daily (n = 282; females, 76%; mean age [range}, 59 [21-85} years), fesoterodine 8 mg once daily (n = 279; females, 78%; mean age [range}, 59 [23-9l} years), or placebo (n = 271; females, 74%; mean age [range}, 59 [24-88} years) for 12 weeks. Subjects completed a 3-day bladder diary before randomization, and at 2, 8, and 12 weeks after initiating treatment, in which the time of each micturition, incontinence episode, and urgency episode was recorded. Primary end points included the change from baseline in the number of micturitions and the mean number of UUI episodes per 24 hours and the treatment response, which was derived from a 4-point treatment benefit scale (l = greatly improved; 2 = improved; 3 = not changed; and 4 = worsened during treatment). The treatment benefit response was considered "Yes" if the score was 1 or 2; "No" if the score was 3 or 4. Secondary efficacy end points were MVV per micturition, and the number of daytime micturitions, nocturnal micturitions, and urgency episodes per 24 hours, and continent days per week. The mean change from baseline in the number of micturitions per 24 hours was statistically significant with fesoterodine 8 mg (-2.09; P < 0.001) and fesorerodine 4 mg (-1.61; P = 0.032) compared with that of placebo. The mean change from baseline in the number ofUUI episodes associated with fesoterodine 8 mg was -2.28 (P < 0.001 vs placebo) and -1.65 (P = 0.003 vs placebo) with fesoterodine 4 mg. Patient-reported treatment-response rates with fesoterodine 8 mg (74%; P < 0.001) and fesoterodine 4 mg (64%; P < 0.001) were statistically significantly higher compared with placebo (45%) at study end. With respect to secondary end points, there was a statistically significant increase in MVV of fesoterodine were assessed in patients (N = 1132) with GAB (Table II) . Patients aged~18 years with~8 micturitions per 24 hours and either~6 urgency episodes or 3 UUI episodes per 24 hours were included in the study. After a 2-week placebo run-in period, the eligible patients were equally randomized to 1 of 4 groups: fesoterodine 4 mg once daily (n = 272; female, 81 %; mean [ for 12 weeks. The primary efficacy end points were change from baseline to week 12 in micturitions per 24 hours, in UUI episodes per 24 hours, and treatment response (which was identical to the primary efficacy end point of Nitti et aFl). Secondary efficacy end points included MVV per micturition, daytime micturitions per 24 hours, nocturnal micturitions per 24 hours, urgency episodes per 24 hours, and continent days per week (calculated based on a 3-day diary). At the end of treatment, there was a statistically significant reduction in the least squares mean change in number of micturitions per 24 hours from baseline in subjects receiving fesoterodine 4 mg (-1.76; P < 0.001 vs placebo), fesoterodine 8 mg (-1.88; P < 0.001), and tolrerodine ER 4 mg (-1.73; P = 0.001). The percentage of subjects who reported a positive treatment response was statistically significantly higher among the subjects receiving fesoterodine 4 mg, fesoterodine 8 mg, and tolrerodine ER 4 mg, than placebo (75%, 79%, 72%, and 53%, respectively; all, P < 0.001 vs placebo). At the end of treatment, the mean change from baseline in UUI episodes per 24 hours was statistically significant for patients receiving fesoterodine 4 mg (-1.95; P = 0.001 vs placebo), fesoterodine 8 mg (-2.22; P < 0.00l), and rolterodine ER 4 mg (-1.74; P = 0.008). The increase in MVV was 3.0, 3.6, and 2.5 times greater than placebo in subjects receiving fesoterodine 4 mg, 8 mg (both, P < 0.00l), and tolterodine ER 4 mg (P = 0.002), respectively. The mean change in daytime micturitions was statistically significant with fesoterodine 4 and 8 mg and tolterodine ER 4 mg compared with placebo (all, P < 0.00l). The mean change in the number of urgency episodes per 24 hours was statistically significant with fesoterodine 4 mg (-1.88; P = 0.003 vs placebo), fesoterodine 8 mg (-2.36; P < 0.00l), and tolterodine ER 4 mg (-2.03; P < 0.001). The mean increase in the number of continent days per week was statistically significant with fesorerodine 4 mg (2.84; P = 0.007 vs placebo) and fesoterodine 8 mg (3.32; P < 0.001), but not significant with tolterodine ER 4 mg (2.48). The mean change in the number of nocturnal micturitions per 24 hours was not statistically significant in any of the groups compared with placebo.F A post hoc analysis of Phase III trials by Khullar er aF3 suggested that fesoterodine was associated with significantly reduced GAB symptoms, including urgency and UUI, in a dose-dependent manner. Fesoterodine 8 mg was associated with a statistically significant improvement in most bladder-diary variables (P < 0.05) compared with fesoterodine 4 mg, with the exception of micturition frequency, for which a numerical, though not statistically significant, decrease was observed.
Another post hoc analysis by Chapple et al 24 concluded that the maximum recommended dose of fesoterodine (8 mg) was significantly (P < 0.05) more effective than the maximum recommended dose of tolterodine ER (4 mg) for improving several important OAB outcomes including incontinence, MVV per void, number of continent days per week, and severe urgency plus UUI.
The efficacy and tolerability of flexible-dose fesoterodine in patients with OAB was assessed by Wyndaele at al 25 in a 12-week, multicenter, open-label, single-arm, flexibledose study (Table III) . Patients aged ;:::18 years (n = 516; female, 77%; mean age, 60 years) with OAB symptoms for ;:::3 months, mean micturition frequency of;:::8 micturitions per 24 hours, and mean number of urgency episodes ;:::3 per 24 hours, who were dissatisfied with previous tolterodine or tolterodine ER treatment (within 2 years of screening) were enrolled. Patients reported being "somewhat dissatisfied" or "very dissatisfied" with tolterodine treatment on the treatment satisfaction question (TSQ), a single item from the validated Overactive Bladder Satisfaction Questionnaire.f'' All of these patients were administered fesoterodine 4 mg once daily for the first 4 weeks. After that, the dose could either be maintained at 4 mg or increased to 8 mg once daily for the remaining 8 weeks. Statistically significant improvements from baseline to week 12 were observed in the mean number of micturitions, UUI episodes, and urgency episodes (all, P < 0.001). Statistically significant improvements in nocturnal micturitions, severe urgency episodes, and frequency-urgency total were also observed at week 12 compared with baseline (all, P < 0.001). After 12 weeks, 80% of patients who responded to the TSQ reported being satisfied with fesoterodine, with 38% being "very satisfied." At that time, 83% of subjects reported improvement on the Patient Perception of Bladder Condition (PPBC) questionnaire.V The percentage of subjects with many severe, severe, and moderate problems were 17.9%, 50.1 %, and 32.0%, respectively. After 12 weeks, 3.1 %,8.8%, and 24.6% had many severe, severe, and moderate problems. Also, 26.3%, 28.1 % and 9.0% of subjects had minor, very minor, or no problems. Mean PPBC scores decreased (improved) significantly from 4.9 at baseline to 3.1 at week 12 (P < 0.001). Improvement in mean scores on the Urgency Perception Scale 28 was statistically significant at week 12 (from 1.8 at baseline to 2.4 at week 12; P < 0.001).
EFFECT ON HRQOL
A post hoc inferential analysis assessed treatment-related effects on HRQoL based on the King's Health Questionnaire (KHQ),29 International Consultation on Incontinence Questionnaire Short Form (lCIQ-SF),30 and a 6-point Likert scale (0 = no problems to 5 = very severe problems), to rate the severity of problem s related to t heir bladder cond it ion, and treatment response (a yes/no variable derived from a 4-point tr eatmentbenefit scale). Patients com pleted the scales at basel ine and end of st udy. The KHQ is a 33-item , multidimension al, disease-specifi c qu esti onn aire wit h 9 domai ns: role limitations, ph ysical lim itations, social limitations, personal relat ionships, emotions, sleep/energy, severity/cop ing, incontinence impact , and general health percepti on. Th e ICIQ-SF assesses th e effects of urinary frequen cy and urine leakage on dail y life. The Likert scale assesses the bladder condition.
There was a st atistically sig nificant change in HRQoL in patients with OAB receiving fesoterodine 4 or 8 mg once daily compared with th ose receiving pla cebo. Th e g roup that received fesot erodine 8 mg had statist ically sig nificant improvem ent s compared with pl acebo in 8 of 9 KHQ domains (ie, all excep t for gene ral health perception). Patients receiving fesoterodine 4 mg or tolterodine ER 4 mg had statistically sig nificant improvements com pa red with placebo in 7 of 9 KHQ domains . Pati ent s receiving fesoterodine 8 mg had sig nificantl y better results than tho se receiving 4 mg in 2 domain s (ie, em ot ions and severity/coping; both , P < (>.05 ); however, th ere was no sta ti st ically sig nificant differen ce between pa ti ent s receiving fesote rod ine 8 mg and tho se receiving tolrerodine ER 4 mg. Improvem ents considered mean ingful to th e patients (ie, change from baseline of~5 po ints) were foun d in all activ e treatment g roups in all but one KHQ domai n (ie, genera l health pe rcep t ion). All act ive treatment g roups reported a sta t istically sig nificant improvement in the ICIQ-SF score compa red with placebo (P < 0.00 1), and there were no sta tistical d ifferences bet ween active tre atment g roups . At the end of the stu dy, th e Liker t scale scores ranged from 2.3 to 2.8 (ind icating minor problem s) compared with a mean of -3 .6 at th e baseline (mode rate to severe pro blems). The pe rcentag e of patients wit h an im provement of 2 points with fesoterodine 4 mg (33%), fesoterodine 8 mg (38 %), and tolterod ine ER 4 mg (34 %) was sta tistically sig nificant compared with pl acebo (all, P < 0 .00 I). The percentage of patients reporting a positive tre atment response was statistically significant in those receiving fesoterodine 4 or 8 mg once daily compared with those receiving placebo (P < 0.001 ).' \1 \XTyndaele et al 25 used the Overact ive Bladder Qu est ionnaire (OAB _q),26 which com prises an 8-item Symptom Bother scale and a 25-item H RQoL scale with 4 domains (concern , cop ing , sleep, and social int eract ion). The mean change in the OA B-q Symptom Bother score, in total HRQoL, and all 4 domains of HRQoL from baseline to week 12 was statistically signifi cant (all, P < 0 .00 1).
SAFETY AND TOLERABILITY
The safety and tol erab il it y profile of fesorer odi ne was st ud ied in 3 Ph ase III trials . 21 . 22 ,25 In the Ph ase II tri al by Nitti er al,20 th e safety pro file offesoterodine was investigated . It was reported th at dr y mouth, headache, and gastroint estinal sym ptoms were the mo st com mo n AEs. The tre atment was di sconti nued by 2.27% , 4 .25 % , 12.80 % , and 4 .6 5% in pati ents receiving fesoterod ine 4 , 8, and 12 mg , and placebo, respecti vely, due to AEs. The Phase III tr ial by Nitti et al 21 report ed th at tre atmentemergent AEs occurred in 6 1% , 69% , and 55% of su bjects receiving fesoterod ine 4 and 8 mg, and placebo, respectively. The most frequently reported AE was mild to moderate dry mouth, reported by 16%, 36%, and 7% of subjects in the fesoterodine 4 and 8 mg, and placebo groups. Urinary retention occurred in 1.41 %,2.15%, and 0.36% of patients receiving fesoterodine 4 and 8 mg and placebo. Other reported AEs were constipation, urinary tract infection, and headache. Chapple et al 22 reported dry mouth in 16.9%,21.7%,33.8%, and 7.15% of patients receiving tolterodine ER 4 mg, fesoterodine 4 and 8 mg, and placebo. Severe dry mouth was reported by 3.0% of patients in the 8-mg fesoterodine group. Other than dry mouth, no AE was reported in > 5% of subjects. Other reported AEs were constipation, headache, and nasopharyngitis. Wyndaele et al 25 reported dry mouth (23%) and constipation (5%) as the most common AEs. Urinary retention requiring catheterization was reported in one female patient who was receiving fesoterodine 8 mg.
Fesoterodine treatment was not associated with any clinically relevant changes in vital signs (eg, heart rate, blood pressure) Ot in laboratory parameters. Fesoterodine 4 and 8 mg once daily was generally well tolerated, and the number of patients who discontinued due to the AEs was low in both clinical trials. 21,22
DOSAGE AND ADMINISTRATION
Fesoterodine is indicated for the treatment of DAB to relieve symptoms of utge incontinence, urgency, and frequency.14,18 The recommended starting dose of fesoterodine is 4 mg once daily; however, it may be increased to 8 mg once daily depending on individual response and rolerabihty.l" The daily dose of fesoterodine should not exceed 4 mg in patients with severe renal insufficiency (CrC! <30 rnL/min) and those taking potent CYF3A4 inhibitors such as keroconazole, itraconazole, and clarithrornycin.l''
CONTRAINDICATIONS
Fesoterodine is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucorna.lv-" It is also contraindicated in patients with severe hepatic impairment (Child Pugh C) and known hypersensitivity to the drug or its ingredients.
PRECAUTIONS
Caution needs ro be exercised in patients with the following: clinically significant bladder outlet obstrucrion (risk of urinary retention); gastrointestinal obstructive disorders (eg, pyloric stenosis); decreased gastrointestinal motility, such as those with severe constipation; severe ulcerative colitis; toxic mega colon; myasthenia gravis; and controlled narrow-angle glaucoma.
DISCUSSION
Based on this review of the literature, fesoterodine is a well-tolerated agent and the pharmacokinetics of its active moiety, 5-HMT, are robust and largely independent of CYP pharmacogenetics. The maximum recommended dose of fesoterodine (8 mg) provided additional benefit compared with the maximum recommended dose of tolterodine ER (4 mg) on several important end points, including reduction in UUI epi-sodes and increase in MVV per void. Fesorerodine , which was g rant ed US Food and Drug Admini strat ion approval in O ctober 2008, 32 is an addit ional treatment op tion for pati ents with OAB . The Scottish Medicines Con sorrium. P based on its assessment, adv ises that fesorer odine should be used as a second-line agent in the National Health Service for Scotl and in view of less expensive antirnuscari nics being availabl e.
Fesoterodine is the newest oral drug available for tr eatment of OAB . Unlike the CYP2 D6-med iated met abolism of rolt erodine to 5-HMT, th e formation of 5-HMT by fesot erodine is medi at ed by nonspecific and ubiquitous escerases.' ? Moreover, multi ple metabol ic (compa rable cont ribu tions from CYP 3A4 and CYP2D6) and renal excretion pathways are involved in the elimination of 5-HMT. Therefore, the effects of patient intrinsic (hep ati c/renal impairment) and extrinsic factors (CYP 3A4 or CYP2D6 in hibition) on th e pharmacokinetics of fesorer od ine are on ly modest. This may generate an advantage com pared wi th rolterod ine.
A poo led post hoc analysis of the Phas e III trials 21 ,22 found that fesoterodine 8 mg was significantly more efficacious than fesoterodine 4 mg for improving UUI episodes , MVV per micturition , continent days per week, and su bject-repon ed treatment response after 12 weeks. The trial by W yndaele er al 2s suggest ed similar results in th e real-world clinical cond iti on . When fesot erodine was used in th e flexible dos ing reg imen , rhere was a significant improvem ent in OAB sympto ms and HrQoL measures. The clinical trials of fesorerod ine have some limitat ions. First , th e onl y study with an active comparator (rolterod ine ER )22 was not powered to detect a statistical difference between fesoterodine and the comparator. Al though the comparat ive results were not available from this Ph ase III tr ial, th e open-label tri al by W yndaele et al found that , at 12 weeks, 80 % of subjects who responded to th e TSQ and who were dissatisfied with their previous treatment (rolterodine ER), reported being satisfied with fesoterodine tr eatment; 38% reported being very satisfied . Second, the durati on of the stu dies was just 12 weeks. Although supporti ve open-label extension stu d ies are ongoing, it is difficult to draw conclusions on efficacy from interim result s. 14 ,34 Thi rd , the W yndaele et al tri al was an open -label , nonra ndom ized , dose-escalation stu dy without a control g roup . Fourth, in the W ynd aele et al trial , no comparison was drawn between the sub ject s who received the 4-mg dose th roughout the study with subjects who escalated to th e 8-mg dose at week 4. Fifth, there were no data pro vided for the reasons for the dose escalation in the same tr ial. Lasrly, in both th e Phase III tri als,21,n pa tients with OAB of neurogenic orig in were not included , therefore lim iting the knowledge about the use of fesoterodine in a very large group of pa tients with OAB .
The prolonged-release formulation of fesoterodine offers an advant age of less freq uent dosing and, consequently, better patient compliance. The benefit of pharmacotherap y for OAB must be a balance between efficacy and tolerability. The availability of 2 different dose s of fesorerodine (4 and 8 mg ) allows for an opportunity to find an op timal balance between efficacy and tolerability in individ ual pat ients. The efficacy of fesorerodine can be tested in patients u nsati sfied with rolterodine trea tment.II This was an attempt co review th e available literature regarding fesorerodine, a relati vely new molecule. A number of clinical trials are currenrly under way to explore th e efficacy, tol erabilit y, and safety pro file in compa rison with established treatments for OAB. A final word about th e use of fesorerodine would be possible once th e data from th ese stu dies are available.
CONCLUSION
A review of the literature sugg ests th at fesorerodine is an efficacious and well-tolerated treatment op tion for pati ents with OAB .
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